NCT07490314

Blood Product Supply

Blood Product Supply During COVID-19

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 100 (actual)
• Sponsor: Methodist Health System · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Data about the links between Coronavirus disease 2019(COVID-19) and the safety of blood products during the pandemic is inadequate. During the COVID-19 pandemic, high volumes of patients receiving blood products due to post-terminal surgical complications depleted stores for the entire hospital, resulting in surgeons unable to acquire emergent blood products. Data from this study can be used to develop a policy on how to handle blood shortage issues during this and future pandemics. Also, this data can be used to determine future policies on use of blood products from COVID-19-positive donors.

Detailed description

* To identify the circumstances associated with observed delays in receiving blood products to use in emergent cases. * Determine the cost/benefit of moribund patients receiving massive transfusion during the COVID-19 pandemic. * Quantify COVID-19 diagnosis and complications in patients arriving with no indication of disease at index admission as relative to in hospital or blood product exposure.

Conditions

• COVID-19

Interventions

Type	Name	Description
OTHER	Document delays and frequencies of inadequate blood products for emergent cases	The COVID-19 pandemic is contributing to delays in blood product acquisition and inadequate blood product supplies for emergent cases in hospitals

Timeline

• Start date: 2020-03-01
• Primary completion: 2021-03-21
• Completion: 2025-06-25
• First posted: 2026-03-24
• Last updated: 2026-03-24

Locations

1 site across 1 country: United States